Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of J4 in Healthy Adults
NCT06938763Phase 1Recruiting
- Sponsor
- Academia Sinica
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of J4 in Alzheimer's disease (AD) (5 arms), sponsored by Academia Sinica. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events. Started Feb 2025; status: recruiting.
02
Drugs
J4
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06938763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938763.